Reproductive Health

2025-2026 Bill 4639: Reproductive Health - South Carolina Legislature Online

South Carolina General Assembly
126th Session, 2025-2026
Download
This Bill
in Microsoft Word Format
Indicates Matter Stricken
Indicates New Matter
H. 4639
STATUS INFORMATION
General Bill
Sponsors: Reps. Oremus, Pope, Cromer, Gatch, G.M. Smith, Hartz, Crawford, Brewer and Sessions
Document Path: LC-0306VR26.docx
Introduced in the House on January 13, 2026
Currently residing in the House
Summary: Reproductive Health
HISTORY OF LEGISLATIVE ACTIONS

Date

Body

Action Description with journal page number

12/16/2025

House

Prefiled

12/16/2025

House

Referred to Committee on
Medical, Military, Public and Municipal Affairs

1/13/2026

House

Introduced and read first time (
House Journal-page 43
)

1/13/2026

House

Referred to Committee on
Medical, Military, Public and Municipal Affairs
(
House Journal-page 43
)

2/18/2026

House

Member(s) request name added as sponsor: Cromer,
Gatch, G.M. Smith, Hartz, Crawford

2/19/2026

House

Member(s) request name added as sponsor: Brewer,
Sessions

View the latest
legislative information
at the website
VERSIONS OF THIS BILL
12/17/2025

A bill

TO AMEND THE SOUTH
CAROLINA CODE OF LAWS BY ENACTING THE "REPRODUCTIVE EMPOWERMENT AND SUPPORT
THROUGH OPTIMAL RESTORATION (RESTORE) ACT" BY ADDING CHAPTER 141 TO TITLE 44 SO
AS TO EXPAND AND PROMOTE RESEARCH AND DATA COLLECTION ON REPRODUCTIVE HEALTH CONDITIONS
THAT ARE LEADING CAUSES OF INFERTILITY, TO PROVIDE TRAINING OPPORTUNITIES FOR
HEALTHCARE PROFESSIONALS REGARDING THE DIAGNOSIS AND TREATMENT OF REPRODUCTIVE
HEALTH CONDITIONS; AND FOR OTHER PURPOSES.

B
e it enacted by the
General Assembly of the State of South Carolina:

S
ECTION 1.
This act may be cited as the "Reproductive Empowerment and Support
Through Optimal Restoration (RESTORE) Act."

S
ECTION 2.
T
he General Assembly finds that:

(
1) There is a
growing interest among women and men to proactively assess their overall health
and understand how factors, such as their age and medical history, contribute
to their reproductive health and fertility.

(
2) Women and men
are worthy of the highest standard of medical care, including the opportunity
to assess, understand, and improve their reproductive health. Yet, many women
and men do not receive adequate information about their reproductive health nor
have access to restorative reproductive medicine.

(
3) Reproductive
health conditions are the leading cause of infertility, affecting eleven
percent of women and nine percent of men in the United States. Leading
conditions include endometriosis, polycystic ovary syndrome, blocked fallopian
tubes, and male-factor infertility.

(
4) Research shows
that male and female infertility is typically due to four or more conditions or
factors, with the diagnosis shared equally between men and women.

(
5) There is a gap
in research and care for reproductive health conditions that affect a majority
of women struggling with "unexplained infertility." Unexplained infertility
accounts for fifteen to thirty percent of all diagnoses of infertility.

(
6) Restorative
reproductive medicine aims to examine how women's reproductive functions and
cycle interact with the rest of the female body.

(
7) Male-factor
infertility and reproductive dysfunction has been on the rise since the 1970s,
with a one percent decrease in sperm count, testosterone, and total fertility
per year.

(
8) Restorative
reproductive medicine can eliminate barriers to successful conception,
pregnancy, and birth. It can also address some causes of recurrent
miscarriages.

(
9) Restorative
reproductive medicine alleviates other difficult symptoms associated with
reproductive health conditions including, but not limited to, painful periods,
painful flare-ups, bloating, inflammation, heavy periods, irregular periods,
nerve pain, bowel symptoms, pain during sexual intercourse, and back pain. It
also addresses common symptoms related to male-factor infertility, including
erectile dysfunction.

S
ECTION 3.
T
itle 44 of the S.C. Code is amended by adding:

C
HAPTER 141

R
eproductive Health

S
ection
44-141-10
.
A
s used in this chapter:

(
1) "Adenomyosis"
means a disease, the cause of which is unknown and often existing concurrently
with endometriosis, that occurs when endometrial tissue, which normally lines
the inside of the uterus, grows down into the muscle layer of the uterus,
increasing the risk of miscarriage and preterm labor, and possibly contributing
to infertility.

(
2) "Assisted
reproductive technology" means any treatments or procedures that involve the
handling of a human egg, sperm, and embryo outside of the body with the intent
of facilitating a pregnancy, including artificial insemination, intrauterine
insemination, in vitro fertilization, gamete intrafallopian fertilization,
zygote intrafallopian fertilization, egg, embryo, and sperm cryopreservation,
and egg or embryo donation.

(
3) "Blocked
fallopian tubes" means a condition where the fallopian tubes are blocked by
tubal spasm, scarring from inflammatory conditions, debris, tubal polyps, tubal
ligation, prior ectopic pregnancy, pelvic adhesions, endometriosis, or prior
pelvic infection, including pelvic inflammatory disease, which is often the
cause of infertility in women, making achieving pregnancy difficult, if not
impossible, and which can be treated with a fallopian tube recanalization,
tubotubal anastomosis (tubal ligation reversal), and
neosalpingostomy/fimbrioplasty.

(
4) "Endometriosis"
means a disease in which tissue resembling endometrial lining tissue grows
outside of the uterus and:

(
a)
adheres to different organs, disfiguring the organs and, through scar tissue or
adhesions;

(
b)
has the capacity to result in organs adhering to the pelvic wall or to one
another, which can impact abdominal organs, the bowel, the diaphragm, the
lungs, the brain, and the eye;

(
c)
is progressive in nature and is often diagnosed in stages, from Stage I, the
mildest form, to Stage IV, the most severe and widespread form;

(
d)
commonly goes undiagnosed for ten to twelve years with women suffering for
years with painful periods, pelvic pain, or infertility; and

(
e)
the cause of which is unknown.

(
5) "Fertility
awareness-based methods" or "FABMs" means modern, evidence-based methods of
tracking the menstrual cycle through observable biological signs in a woman,
such as body temperature, cervical fluid, and hormone production in the
reproductive system, including luteinizing hormone (LH) and estrogen, and
includes Fertility Education and Medical Management, the symptothermal method,
the Marquette method, the Creighton method, and the Billings ovulation method.

(
6) "Fertility
education and medical management" or "FEMM" means the program developed in
collaboration with the Reproductive Health Research Institute for medical
research, protocols, and medical training for healthcare professionals in order
to enable the clinical application of important research advances in
reproductive endocrinology, by providing education for women about their bodies
and hormonal health and medical support, as appropriate.

(
7) "Infertility"
means a symptom of an underlying disease or condition within a person's body
that makes it difficult or impossible to successfully conceive and carry a live
child to term where it should otherwise be possible through intercourse with a
person of the other sex. A diagnosis of infertility often occurs after twelve
months of targeted intercourse for women under thirty-five years of age, or
after six months of targeted intercourse without the use of a chemical,
barrier, or other contraceptive method for women thirty-five and older.

(
8) "Natural
procreative technology" or "NaProTechnology" means an approach to healthcare
that monitors and maintains a woman's reproductive and gynecological health,
including laparoscopic gynecologic surgery to reconstruct the uterus, fallopian
tubes, ovaries, and other organ structures to eliminate endometriosis and other
reproductive health conditions.

(
9)
"Polycystic ovary syndrome" means a reproductive hormonal disorder that causes
cysts to grow on the ovaries, usually as a result of hormonal imbalances,
which:

(
a)
affects approximately fifteen percent of women overall but is more common among
women with infertility;

(
b)
is more prevalent among women with obesity and insulin resistance; and

(
c)
often impacts women with underlying hormonal imbalances, many of whom are
commonly prescribed oral ovulation medication and hormonal injections that
stimulate ovulation when trying to achieve pregnancy and who would benefit from
accurate and timely diagnosis and treatment to correct the underlying hormonal
imbalances, which is critical for both long-term health improvements as well as
for fertility outcomes.

(
10)
"Reproductive health condition" means any health condition including, but not
limited to, endometriosis, adenomyosis, polycystic ovary syndrome, uterine
fibroids, blocked fallopian tubes, hormone imbalances, hyperprolactinemia,
thyroid conditions, and ovulation dysfunctions, that makes it difficult or
impossible to successfully conceive a child where conception should otherwise
be possible.

(
11)
"Restorative reproductive health" means healthcare that empowers women and men
to know and understand their bodies and appreciate the importance of natural
reproductive health to overall health and well-being, including through the use
of body literacy programs that incorporate science-based charting methods,
teacher-led reproductive health education, restorative reproductive medicine,
natural procreative technology, fertility awareness-based methods, and
fertility education and medical management.

(
12)
"Restorative reproductive medicine" or "RRM" means any scientific approach to
reproductive medicine that seeks to cooperate with or restore the normal
physiology and anatomy of the human reproductive system. It does not employ
methods that are inherently suppressive, circumventive, or destructive to the
human body.

(
13)
"Uterine fibroids" means muscular tumors that grow in the wall of the uterus,
the cause of which is unknown, and which:

(
a)
can lead to pain and heavy bleeding if the tumors are large enough or embedded
far enough in the uterine lining;

(
b)
can increase risks of preterm labor, pregnancy complications leading to a
cesarean section, and placental abruption, among other risks, and

(
c)
can be treated with a hysteroscopic myomectomy, abdominal myomectomy, uterine
fibroid embolization, or uterine artery embolization.

S
ection
44-141-15
. Notwithstanding any other provision of law, nothing in this chapter
shall be construed to require hospitals, individuals, employees, grantees,
contractors, or entities to violate their consciences, religious beliefs, or
moral convictions by requiring them, or holding them liable for refusing, to
provide any healthcare referenced in this chapter.

S
ection
44-141-20
.
N
otwithstanding any other provision of state
law, a person or entity, including state and local government agencies, that
receives state or local financial assistance, including state-administered
federal funds or local government funds, shall not penalize, retaliate against,
or otherwise discriminate against a healthcare provider on the basis that the
healthcare provider does not, or declines to:

(
1)
assist in, receive training in, provide, perform, refer for, pay for, or
otherwise participate in assisted reproductive technology; or

(
2)
facilitate or make arrangements for any of the activities under item (1) in a
manner that violates the healthcare provider's sincerely held religious beliefs
or moral convictions.

S
ection
44-141-25
.
(
A) The Director of the
Department of Public Health shall implement data collection and produce a
report every three years on the standard of care for women with infertility
diagnoses.

(
B)
In carrying out the data collection under subsection (A), the Director of the
Department of Public Health must:

(
1)
collect and assess data related to restorative reproductive medicine prior to
referral for or use of assisted reproductive technology. For purposes of this
item, restorative reproductive medicine may include ultrasounds, blood tests,
hormone panels, laparoscopic and exploratory surgeries, examining the woman's
overall health and lifestyle, eliminating environmental endocrine disruptors,
and assessing her partner's health and fertility;

(
2)
collect and assess data related to access to information and training for
fertility awareness-based methods; and

(
3)
assess group health plans or issuers of group or individual health insurance
coverage of the treatments, tests, and training addressed by this subsection.

(
C)
In carrying out the data collection pursuant to subsection (A), the Director of
the Department of Public Health shall ensure that the privacy and
confidentiality of individual patients are protected in a manner consistent
with relevant privacy and confidentiality laws.

(
D)
No later than two years after the date of enactment of this chapter, the
Director of the Department of Public Health shall submit the report to the
Governor and the General Assembly and make publicly available on the website of
the Department of Public Health a report on the data collection carried out pursuant
to this section.

S
ection
44-141-30
.
(
A) The Director of the
Department of Public Health shall implement data collection and produce a
report every three years on the standard of care for women and men seeking
reproductive health condition diagnoses.

(
B)
In carrying out the data collection under subsection (A), the Director of the
Department of Public Health must:

(
1)
collect and assess data related to access to restorative reproductive medicine
and restorative reproductive health, including access to medical professionals
trained in NaProTechnology and FEMM;

(
2)
collect and assess data related to access to information and training on
fertility awareness-based methods; and

(
3)
assess group health plans or issuers of group or individual health insurance
coverage of the treatments, tests, and training addressed by this subsection.

(
C)
In carrying out the data collection pursuant to subsection (A), the Director of
the Department of Public Health shall ensure that the privacy and
confidentiality of individual patients are protected in a manner consistent
with relevant privacy and confidentiality laws.

(
D)
No later than two years after the date of enactment of this chapter, the
Director of the Department of Public Health shall submit the report to the
Governor and the General Assembly and make publicly available on the website of
the Department of Public Health a report on the data collection carried out pursuant
to this section.

S
ection
44-141-35
.
(
A) All Title X-funded
facilities in the State must include fertility awareness-based methods as part
of covered family planning and reproductive health services.

(
B)
(
1) The Department of Public Health
shall work with Title X‐funded facilities to integrate fertility
awareness-based methods into existing programs within twelve months of the
effective date of this chapter.

(
2)
The department shall provide guidance and support to facilities in implementing
the fertility awareness-based methods, including:

(
a)
training for healthcare providers on fertility awareness-based methods; and

(
b)
development of patient education materials on fertility awareness-based
methods.

(
C) Consistent
with federal law, Title X‐funded facilities shall allocate a portion of
existing Title X funds to cover implementing and providing fertility
awareness-based methods.

(
D)
Compliance with this section is a condition of state licensing of Title X
facilities.

S
ection
44-141-40
.
(
A) The State Department
of Health and Human Services shall not exclude entities that provide
restorative reproductive medicine, as defined in this chapter, from receiving
the grants and contracts provided to other Title X entities, provided they meet
all other qualifications.

(
B)
The State Department of Health and Human Services may not exclude entities that
provide training and education for medical students and professionals in
restorative reproductive medicine, as defined in this chapter, from receiving
the grants and contracts provided to other Title X entities, provided they meet
all other qualifications.

S
ection
44-141-45
.
(
A) The Director of the Department of
Public Health shall develop within the already existing state health education
standards and public health program curricula to include information on
reproductive health conditions, restorative reproductive medicine, restorative
reproductive health, and fertility awareness-based methods. For purposes of
this subsection, public health programs include family planning services, maternal
and child health programs, and women's health initiatives.

(
B)
No later than eighteen months after the date of enactment of this chapter, the
Director of the Department of Public Health shall make publicly available a
report on the updated curriculum standards for public health programs and a
plan for regular reporting on their outcomes.

(
C) The
Director of the Department of Public Health shall ensure that any grant or
partnership opportunities within these programs are advertised to and inclusive
of organizations that specialize in restorative reproductive health and
fertility awareness education.

S
ection
44-141-50
.
(
A) The Director of the
Department of Public Health shall ensure, by oversight, that the Board of
Medical Examiners update professional education and licensing requirements as
needed to include training in restorative reproductive medicine, restorative reproductive
health, and fertility awareness-based methods through the management of their
healthcare license.

(
B)
(
1) The Department of Public Health
must provide training to staff working at Title X providers on reproductive
health conditions, restorative reproductive medicine, restorative reproductive
health, and fertility awareness-based methods.

(
2)
The training required pursuant to this subsection may include RRM, FEMM, and
FABM toolkits, peer learning opportunities, NaProTechnology educational
fellowships, education addressing FEMM and FABMs, short videos on reproductive
health conditions and restorative reproductive medicine, and contracts with
medical professionals for seminars and training on RRM, NaProTechnology, FEMM,
and FABMs.

S
ection
44-141-55
.
(
A) The Director of the
Department of Public Health shall expand and coordinate programs to conduct and
support research on reproductive health conditions.

(
B)
The Director of the Department of Public Health shall implement this research
initiative within the Department of Public Health and any other subagency,
public health research division, or research university already conducting
research on reproductive health conditions, infertility, and maternal health.

(
C)
In carrying out the research pursuant to subsection (A), the Director of the
Department of Public Health may:

(
1)
direct research on the causes of reproductive health conditions, especially
endometriosis, adenomyosis, uterine fibroids, and polycystic ovary syndrome;

(
2)
direct research on ways to diagnose reproductive health conditions;

(
3)
direct research on restorative reproductive medicine and new treatment options
for reproductive health conditions;

(
4)
direct targeted research on endocrine-disrupting chemicals in endometriosis,
the relationship of endometriosis and cancer, and prenatal and epigenetic
influences on the risk for endometriosis;

(
5)
direct research on the growth and progression of reproductive health conditions
and recurrence post-surgical procedures;

(
6)
direct research on male mechanisms of infertility, such as low sperm count, low
sperm motility, erectile dysfunction, low testosterone, varicocele, and
testicular torsion;

(
7)
direct research on the effectiveness of fertility awareness-based methods to
achieve pregnancy and increase the number of live births;

(
8)
direct research on premenstrual syndrome, hormonal dysfunctions, ovulation
defects, abnormal uterine bleeding, adhesion prevention, tubal corrective
surgery, and preconception health;

(
9)
direct research on the prevalence of sexually transmitted infections and their
effects on fertility in both men and women; and

(
10)
direct research on the impact of exposure to environmental factors like microplastics
on male and female reproductive health, including sperm quality.

(
D)
No later than twenty-four months after the date of enactment of this chapter,
the Director of the Department of Public Health shall make a report on the
research publicly available. This report should be updated annually.

S
ection
44-141-60
.
(
A) The Department of
Public Health shall expand and coordinate programs, within existing public
health or family planning initiatives, for the development of education,
awareness, and treatment for male factor infertility through lifestyle and
metabolic modifications.

(
B)
The programs required by subsection (A) must address, at minimum, low sperm
count, sperm motility, sperm morphology, hormonal imbalances, sexually
transmitted infections, obesity, varicoceles, and erectile dysfunction.

(
C)
No later than twenty-four months after the date of enactment of this chapter,
the Director of the Department of Public Health shall make a report on the
research publicly available, along with the developed plans for education and
treatment for male factor infertility within the existing state public health
and family planning programs. This report should be updated annually.

S
ection
44-141-65
.
(
A) The Director of the
Department of Public Health shall collaborate with local and federal
policymakers to recommend updated diagnostic and procedural codes related to
infertility treatments to reflect the latest knowledge and practices in
restorative reproductive medicine.

(
B)
The General Assembly shall recommend a thorough federal review of the
International Classification of Diseases, 10th Revision, Clinical Modification
(ICD-10-CM), the International Classification of Diseases, 10th Revision,
Procedure Coding System (ICD-10-PCS), the Current Procedural Terminology (CPT)
code set, and the Healthcare Common Procedure Coding System (HCPCS). Codes
should be revised and developed for:

(
1)
endometriosis, polycystic ovary syndrome, uterine fibroids, adenomyosis,
blocked fallopian tubes, and male mechanisms of infertility to ensure accurate
classification of severe, chronic reproductive health conditions requiring
medical or surgical intervention;

(
2)
laparoscopic excision, hysteroscopic procedures, and other minimally invasive
surgeries aimed at addressing such conditions, including the excision of
fibroids, ovarian cysts, and adenomyosis-related tissue removal;

(
3)
minimally invasive surgeries and other interventions that target
infertility-related conditions, specifically including laparoscopic excision,
differentiation between laparoscopic ablation and laparoscopic excision of
endometriosis, appendectomy related to endometriosis, bowel resection related
to endometriosis, hysteroscopic myomectomy, abdominal myomectomy, cystectomy,
other minimally invasive procedures that directly treat underlying reproductive
health conditions, and for family planning services, specifically including
female cycle charting instruction; and

(
4)
ensuring appropriate reimbursement under the Medicare and Medicaid programs for
reproductive health-related surgical procedures, postoperative care, and family
planning services, specifically including female cycle charting instruction.

S
ECTION 4. If any section, subsection,
paragraph, subparagraph, sentence, clause, phrase, or word of this act is for
any reason held to be unconstitutional or invalid, such holding shall not
affect the constitutionality or validity of the remaining portions of this act,
the General Assembly hereby declaring that it would have passed this act, and
each and every section, subsection, paragraph, subparagraph, sentence, clause,
phrase, and word thereof, irrespective of the fact that any one or more other
sections, subsections, paragraphs, subparagraphs, sentences, clauses, phrases,
or words hereof may be declared to be unconstitutional, invalid, or otherwise
ineffective.

S
ECTION 5. This act takes effect upon approval
by the Governor.

----XX----

This web page was last updated on January 13, 2026 at 2:43 PM